GLMD vs MDGL vs AKBA vs HALO vs CPRX

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 18. 6x trailing P/E (16. 5x forward), making it the more compelling value choice. Analysts rate Madrigal Pharmaceuticals, Inc. (MDGL) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Catalyst Pharmaceuticals, Inc.

(CPRX) is the cheapest at 18. 6x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus Catalyst Pharmaceuticals, Inc. 's 0. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Catalyst Pharmaceuticals, Inc.

(CPRX) delivered a total return of +545. 2%, compared to -99. 9% for Galmed Pharmaceuticals Ltd. (GLMD). Over 10 years, the gap is even starker: CPRX returned +48. 0% versus GLMD's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Galmed Pharmaceuticals Ltd. 's 1. 98β — meaning GLMD is approximately 287% more volatile than HALO relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, CPRX leads at 40. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Catalyst Pharmaceuticals, Inc.

(CPRX) is the more profitable company, earning 36. 4% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus Catalyst Pharmaceuticals, Inc. 's 0. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 0x forward P/E versus 16. 5x for Catalyst Pharmaceuticals, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Galmed Pharmaceuticals Ltd. (GLMD) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, GLMD: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLMD is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; AKBA is a small-cap high-growth stock; HALO is a small-cap high-growth stock; CPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.